quant Healthcare Fund - Growth Option - Regular Plan

Open Ended Schemes(Equity Scheme - Sectoral/ Thematic)Very High Riskvs Nifty Healthcare TRIISIN INF966L01CG3

NAV · 06-Jul-2026

₹17.3642

+6.93%

+14.46%

1Y (CAGR)

+9.13%

3Y (CAGR)

—

5Y (CAGR)

—

Since inception (CAGR)

+20.39%

NAV history

hover for values

Risk & SIP analytics

Volatility (3y)

17.23%

Downside dev (3y)

12.83%

Max drawdown (3y)

-25.8%

SIP XIRR (3y)

+13.91%

Calendar-year returns

2024 +29.7%2025 -5.2%

Vs benchmark — Nifty 50

3y monthly · 36 months of overlap

Beta

0.91

Alpha (p.a.)

+12.12%

Up capture

131.6%

Down capture

64.0%

Correlation

0.69

Top holdings

AMFI disclosure · 2025-01-01

Divi's Laboratories LimitedEQU-Equity Shares

9.57%

RPG Life Sciences LimitedEQU-Equity Shares

9.28%

Aster DM Healthcare LimitedEQU-Equity Shares

9.22%

IPCA Laboratories LtdEQU-Equity Shares

7.42%

Torrent Pharmaceuticals LtdEQU-Equity Shares

7.31%

Alivus Life SciencesEQU-Equity Shares

7.20%

Zydus Lifesciences LimitedEQU-Equity Shares

7.02%

Aurobindo Pharma LimitedEQU-Equity Shares

6.82%

Reliance Industries LimitedEQU-Equity Shares

6.69%

Zydus Wellness LtdEQU-Equity Shares

5.83%

Fund facts

Fund managerSanjeev Sharma · Ankit A. Pande · Sandeep Tandon · Varun Pattani · Sameer Kate · Ayusha Kumbhat · Yug Tibrewal

AUM₹3,724 Cr

TER · AMFI officialDirect 1.38% · Regular 3.01% (2026-06-30)

Launch date27-Jun-2023

Plan typeOpen Ended · Equity

Min lumpsum5000

Lock-inNone

Volatility17.18

AMCquant Money Managers Limited

Objective · The primary investment objective of the scheme is to provide capital appreciation by investing in equity and equity related instruments including derivatives and debt and money market instruments. However, there can be no assurance that the investment objective of the Scheme will be realized, as actual market movements may be at variance with anticipated trends.

scheme documents ↗